Drug intelligence / Profile preview

LNK011

Development stage: Preclinical
Lead developer: Lynk Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

LNK011 is an oral, small molecule molecular glue degrader (MGD) developed by Lynk Pharmaceuticals. It is designed to target and induce the degradation of Vav guanine nucleotide exchange factor 1 (VAV1), a key signaling protein downstream of T-cell and B-cell receptors that is highly expressed in hematopoietic cells. By promoting the CRBN-dependent degradation of VAV1, LNK011 aims to suppress aberrant immune cell activation and reduce the production of inflammatory cytokines. The drug is currently in preclinical development for the treatment of autoimmune and inflammatory disorders, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Targets

VAV1 (Guanine nucleotide exchange factor VAV1)

Beyond the preview

Go deeper on LNK011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNK011.

Explore the full profile